| Literature DB >> 33552246 |
Jun Han1, Chongchong Wu2, Yuxin Wu3, Hui Deng4, Jie Gao5, Hua Han6, Xinying Xue4.
Abstract
Patients with pneumonia-type lung cancer (PTLC) do not exhibit specific clinical features, which makes imaging diagnosis difficult. Therefore, the aetiology of the pathological changes occurring during PTLC remains unclear. The current study aimed to explore the possible mechanism of PTLC formation by CT scans and pathological analysis of the lungs. A retrospective analysis was conducted on the CT and pathological data of 17 cases of PTLC. The diagnosis of lung cancer was confirmed by pathology. The CT scans of nine patients indicated diffuse distribution of lesions in the lungs, whereas those of three patients indicated single-lung multi-leaf distribution, and those of the remaining five patients included single-leaf distribution. All patients demonstrated increased plaque or patchy density in the majority of the lesions located near the heart. The pathological types of the identified tumours were mucinous adenocarcinoma with adherent growth as the main sub-type. A large number of mucus lakes were observed, containing floating tumour cells, as determined by optical microscopy. In addition, a number of tumour cells were located in the residual alveolar wall of the observed mucus lakes. The results of the present study suggested that the mucinous adenocarcinoma tumour cells produced substantial quantities of mucus, and that the cells were scattered and planted along with the mucus through the airway, which led to possible development of pneumonia-type mucinous adenocarcinoma. Copyright: © Han et al.Entities:
Keywords: lung computed tomography; mucinous adenocarcinoma; pathology; pneumonic mucinous adenocarcinoma
Year: 2020 PMID: 33552246 PMCID: PMC7798099 DOI: 10.3892/ol.2020.12386
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Basic information of the patients included in the present study.
| No. | Smoking, years | Clinical symptoms | CT manifestation | Location | Diagnosis method | Therapeutic measures | Prognosis/survival time |
|---|---|---|---|---|---|---|---|
| 1 | NOT | No cough or expectoration | Flaky density, peripheral ground glass density and cavity | Lower lobe of the left lung | Lobectomy of the left lower lobe | Lobectomy | >60 months |
| 2 | NOT | Cough | Flaky density, peripheral ground glass density, air bronchogenic signs | Lower lobe of the right lung | Lobectomy of the right lower lobe | Lobectomy | 3 months |
| 3 | NOT | Cough, expectoration | Flaky density, peripheral ground glass density | Lower lobe of the right lung | Lobectomy of the right lower lobe | Lobectomy | 4 months |
| 4 | NOT | Cough, expectoration | Flaky density, air bronchogenic signs | Lower lobe of the left lung | Ultrasound-guided lung puncture | Expectant treatment | 4 months |
| 5 | 40 | Cough, expectoration | Flaky density, peripheral ground glass density | Upper lobe of the right lung | Ultrasound-guided lung puncture | Chemotherapy | 6 months |
| 6 | 40 | Cough, expectoration | Flaky density, peripheral ground glass density | Upper lobe of the left lung | CT-guided lung puncture | Chemotherapy | 6 months |
| 7 | NOT | Expectoration | Flaky density, air bronchogenic signs | Upper lobe of the right lung | CT-guided lung puncture | Chemotherapy | 5 months |
| 8 | NOT | Cough, expectoration | Flaky density, peripheral ground glass density and cavity | The right lung | CT-guided lung puncture | Chemotherapy | 8 months |
| 9 | 30 | Cough, expectoration | Flaky density, peripheral ground glass density | Bilateral lungs | CT-guided lung puncture | Chemotherapy | 6 months |
| 10 | 30 | Cough, expectoration | Flaky density, peripheral ground glass density and cavity, air bronchogenic signs | Bilateral lungs | Ultrasound-guided lung puncture | Chemotherapy | 5 months |
| 11 | 25 | Cough, expectoration | Flaky density, peripheral ground glass density | Bilateral lungs | CT-guided lung puncture | Chemotherapy | 12 months |
| 12 | NOT | Cough, expectoration | Flaky density, peripheral ground glass density | Bilateral lungs | Ultrasound-guided | Chemotherapy lung puncture | >60 months |
| 13 | NOT | Cough, expectoration | Flaky density, peripheral ground glass density | Bilateral lungs | CT-guided lung puncture | Chemotherapy | 5 months |
| 14 | NOT | Cough, expectoration | Flaky density, peripheral ground glass density | Bilateral lungs | CT-guided lung puncture | Chemotherapy | 10 months |
| 15 | 30 | Cough, expectoration | Flaky density, air bronchogenic signs, tree bud signs | Bilateral lungs | CT-guided lung puncture | Chemotherapy | 9 months |
| 16 | 20 | Cough, expectoration | Flaky density, peripheral ground glass density | Bilateral lungs | CT-guided lung puncture | Chemotherapy | 12 months |
| 17 | 30 | Cough, expectoration | Flaky density, peripheral ground glass density | Bilateral lungs | CT-guided lung puncture | Chemotherapy | 10 months |
TNM, Tumor-Node-Metastasis.
Figure 1.CT manifestations of mucinous adenocarcinoma (A) The distribution of patchy density of mucinous adenocarcinoma in the upper lobe of right lung. (B) The distribution of patchy density of mucinous adenocarcinoma in the upper lobe of the left lung. (C) The distribution of patchy density of mucinous adenocarcinoma in the middle and lower lobe of right lung. (D) The distribution of patchy density of mucinous adenocarcinoma in the middle and lower lobe of right lung. (E) The distribution of patchy density of mucinous adenocarcinoma in the lower lobe of both lungs. (F) The distribution of patchy density of mucinous adenocarcinoma in both lungs. (G) The distribution of patchy density of mucinous adenocarcinoma in both lungs, mainly in the outer zone. (H) Ground glass opacity distribution of mucinous adenocarcinoma of both lungs. (I) Patchy and ground glass opacity distribution of mucinous adenocarcinoma of both lungs. (J) Coronal reconstruction of a bilateral distribution of patchy density in mucinous adenocarcinoma.
Figure 2.Comparison of CT findings and pathology (A) Black arrow indicates the air bronchogram. (B) H&E staining of lung mucinous adenocarcinoma tissue obtained by puncture biopsy. Magnification, ×100. White arrow indicates the mucus, and the black arrow indicates the wall of the bronchus. (C) Black arrow indicates the vacuole sign. (D) H&E staining of lung mucinous adenocarcinoma tissue. Magnification, ×400. White arrow indicates the mucus and cell nucleus fragments, and black arrow indicates tumour cells.
Figure 3.Comparison of ground glass opacity near the heart end with pathology (A) White arrow indicates the ground glass density in the near end of the heart shadow. (B and C) H&E staining of mucinous adenocarcinoma of the lung. Magnification, (B) ×100 and (C) ×400. Back arrow indicates the tumour cells, and white arrow indicates the mucus.
Figure 4.TTF-1 staining. Immunohistochemistry of TTF-1 in mucinous adenocarcinoma tumour cells. The cells were TTF-1 positive. Magnification, ×400. TTF-1, thyroid transcription factor-1.
Figure 5.Bronchoscopy and ROSE results. (A) Bronchoscopic examination revealed a fountain of mucus from the trachea. (B) ROSE revealed that the dark stained cells were mucinous adenocarcinoma cancer cells. ROSE, rapid on-the-spot evaluation.
Figure 6.Follow-up characteristics of patient no. 3. The lesions in the left lower lobe of the lung were gradually enlarged, whereas those in the right lower lobe did not notably change.
Figure 7.Follow-up characteristics of patient no. 8. At 3 months post-lobectomy, the ground glass density disappeared.